Angelica gigas Nakai (Korean Dang-gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy - active Phytochemicals and In Vivo Molecular Targets

被引:0
|
作者
Lu, Junxuan [1 ,2 ,3 ]
Jiang, Cheng [1 ,3 ]
Drabick, Joseph J. [2 ,4 ]
Joshi, Monika [2 ,4 ]
Perimbeti, Stuthi [2 ,4 ]
机构
[1] Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA 17033 USA
[2] Penn State Univ, Penn State Canc Inst, Hershey, PA 17033 USA
[3] Penn State Univ, Ctr Cannabis & Nat Prod Pharmaceut, Coll Med, Hershey, PA 17033 USA
[4] Penn State Univ, Coll Med, Dept Med, Div Hematol & Oncol, Hershey, PA 17033 USA
关键词
decursin; decursinol; decursinol angelate; nodakenin; ROCK1/2; DECURSINOL ANGELATE; COMPOUND; PHARMACOKINETICS; IDENTIFICATION; MICE; PYRANOCOUMARINS; DECARBOXYLASE; ANTIANDROGEN; INHIBITION; METABOLISM;
D O I
10.1007/s11095-024-03809-9
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Angelica gigas Nakai (AGN) root is a medicinal herbal widely used in traditional medicine in Korea. AGN root ethanolic extracts have been marketed as dietary supplements in the United States for memory health and pain management. We have recently reviewed the pharmacokinetics (PK) and first-pass hepatic metabolism of ingested AGN supplements in humans for the signature pyranocoumarins decursin (D, C-max 1x), decursinol angelate (DA, C-max similar to 10x) and their common botanical precursor and hepatic metabolite decursinol (DOH, C-max similar to 1000x). Here we update in vivo medicinal activities of AGN and/or its pyranocoumarins and furanocoumarin nodakenin in cancer, pain, memory loss, cerebral ischemia reperfusion stroke, metabolic syndrome and vascular endothelial dysfunctions, anxiety, sleep disorder, epilepsy, inflammatory bowel disease, osteoporosis and osteoarthritis. Given their polypharmacology nature, the pertinent mechanisms of action are likely misrepresented by many cell culture studies that did not consider the drug metabolism knowledge. We report here Rho-associated protein kinases (ROCK1/2) as novel targets for DA and DOH. Combining with published inhibitory activity of DOH on acetylcholinesterase, agonist activity of DOH and antagonist/degrader activity of DA/D on androgen and estrogen receptors, D/DA promoting activity for glutamic acid decarboxylase (GAD)- gamma-aminobutyric acid (GABA) inhibitory axis and inhibition of glutamate dehydrogenase (GDH), monoamine oxidase-A (MAO-A) and transient receptor potential vanilloid 1 (TRPV1), we postulate their contributions to neuro-cognitive, metabolic, oncologic, vascular and other beneficial bioactivities of AGN extracts. A clinical trial is being planned for an AGN extract to manage side effects of androgen deprivation therapy in prostate cancer patients.
引用
收藏
页码:25 / 47
页数:23
相关论文
empty
未找到相关数据